Biotech Values

[bellweather1]

PGS,

Do you have an opinion on why the Site vs IRC results for PFS in phase III of the Succeed trial (ridaforolimus in sarcomas) were so different aside from the obvious reason of investigator bias?

I posted a theory after listening to Harvey Berger answer a question about it monday, but got no responses from the Ariad board(post #5638).

Maybe it's a little too deep in the weeds for their tastes, but, since I don’t know very much about CT assessment, I was wondering what you, or some of the more science-minded on this board may think?

Thanks in advance.

Regards,

bw